March 9, 2016

AngioDynamics to Market Merz's Asclera for Vein Patients in the United States

March 10, 2016—AngioDynamics announced an agreement with Merz North America, the United States affiliate of the global Merz Pharma Group, to serve as the exclusive distributor in the United States market for Merz’s Asclera (polidocanol) injection within the vein.

Asclera adds to AngioDynamics' venous disease treatment options, which include the VenaCure EVLT endovenous laser vein treatment system. The Merz partnership replaces previous distribution agreements.

According to AngioDynamics, Asclera is approved for the treatment of uncomplicated spider and uncomplicated reticular veins. In a multicenter, randomized, double-blind, placebo and comparator-controlled trial in patients with spider or reticular varicose veins, 95% of patients treated with Asclera showed good improvement or complete treatment success, as rated by physicians, and 87% of patients were satisfied or very satisfied with their Asclera treatment.

Subscribe to our weekly newsletter.

Stay informed on the week's top stories including literature summaries, device approvals, guideline changes, and more. Plus, get our latest issues & supplements delivered to your inbox each month.

March 9, 2016

AngioDynamics to Market Merz's Asclera for Vein Patients in the United States

Current Issue

Keep In Touch